Induction of the ABC-transporters Mdr1/P-gp (Abcb1), Mrp1 (Abcc1), and Bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone

Journal of Chemotherapy

Volumn 17, Issue 2, 2005, Pages 215-223

  Nieth, C ^a   Lage, H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ABC transporters; ABCB1; ABCC1; ABCG2; Drug resistance; Mitoxantrone

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; ETOPOSIDE; GLYCOPROTEIN P; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TOPOTECAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EXPOSURE; DRUG TRANSPORT; GENE AMPLIFICATION; IC 50; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PUMP; UPREGULATION;

EID: 19544393343     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.2.215     Document Type: Article

References (24)

1. Alberts DS, Griffith KS, Goodman GE, Herman TS, Murray E. Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug. Cancer Chemother Pharmacol 1980; 5: 11-15.
2. Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (((2-[(2-hydroxyethyl)amino]ethyl) amino)) -9,10-anthracenedionedihydrochloride (NSC 301739), a new anthracenedione. Cancer Res 1980; 40: 1516-1518.
3. Edan G, Morrissey S, Le Page E. Rationale for the use of mitoxantrone in multiple sclerosis. J Neurol Sci 2004; 223: 35-39.
4. Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1998; 1400: 173-184.
5. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
6. Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 2003; 22: 188-199.
7. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468-7485.
8. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003; 22: 7537-7552.
9. Lage H, Dietel M. Effect of the breast cancer resistance protein on atypical multidrug resistance. Lancet Oncol 2000; 1: 169-175.
10. Kellen JA. The reversal of multidrug resistance: an update. J Exp Ther Oncol 2003; 3: 5-13.
11. Robert J, Jarry C. Multidrug resistance reversal agents. J Med Chem 2003; 46: 4805-4817.
12. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10: 159-165.
13. Davies PJ, Willecke K. Segregation of human hypoxanthine phosphoribosyltransferase activity from somatic cell hybrids isolated after fusion of mouse gene transfer cells with Chinese hamster cells. Mol Gen Genet 1977; 154: 191-197.
14. Willecke K, Klomfass M, Mierau R, Döhmer J. Interspecies transfer via total cellular DNA of the gene for hypoxanthine phosphoribosyltransferase into cultured mouse cells. Mol Gen Genet 1979; 170: 179-185.
15. Puck TT, Cieciura SJ, Robinson A. Genetics of somatic mammalian cells. III. Long-term cultivation of euploid cells from human and animal subjects. J Exp Med 1958; 108: 945-956.
16. Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 2003; 545: 144-150.
17. Wichert A, Stege A, Midorikawa Y, Holm PS, Lage H. Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene 2004; 23: 945-955.
18. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
19. Stege A, Priebsch A, Nieth C, Lage H. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther 2004; 11: 699-706.
20. Lage H, Dietel M. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. J Cancer Res Clin Oncol 2002; 128: 349-357.
21. Roos G. Mitoxantrone sensitivity of human hematopoietic cell lines. Leuk Res 1987; 11: 519-524.
22. Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 1986; 232: 643-645.
23. Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. Gene rearrangement: a novel mechanism for MDR1 gene activation. J Clin Invest 1997; 99: 1947-1957.
24. Knutsen T, Mickley LA, Ried T, et al. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene MDR1/P-glycoprotein in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer 1998; 23: 44-45.